Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

ew product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Summary financial statements attached:YM BIOSCIENCES INC.
Interim Consolidated Balance Sheets
(Expressed in Canadian dollars, unless otherwise noted) September 30,  June 30, 2010 2010 (Unaudited)   Assets Current assets:   Cash and cash equivalents
$  15,095,919 $
9,460,141   Short-term deposits
25,073,158
26,184,991   Accounts receivable
,007
,184   Prepaid expenses
24,428
237,962 40,459,512
46,044,278 Property and equipment
28,855
84,775 Intangible asset
,518,7
,645,714 $
51,107,077 $
57,774,767 Liabilities and Shareholders' Equity Current liabilities:   Accounts payable
$ 693,188 $
99,277   Accrued liabilities
2,729,655
2,085,824   Deferred revenue
594,072
,523,916 4,016,915
4,309,017 Deferred revenue
2,277,27
,650,909 Shareholders' equity:   Share capital
203,522,4
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500â„¢
9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
11. Cell Biosciences to Acquire Convergent Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... WASHINGTON D.C., June 17, 2014 Using microscopic ... of specific gases, researchers at MIT,s Quantum Photonics ... detection levels in the parts-per-billion range. Optical sensors ... to their high signal-to-noise ratio, compact, lightweight nature, ... optical gas sensors had been developed before, the ...
(Date:7/10/2014)... power our laptops and electric vehicles could store more ... the help of a sponge-like silicon material. , ... traditionally used in one of the battery,s electrodes, as ... capacity of graphite. A paper describing the material,s performance ... Nature Communications . , "Silicon has long been ...
(Date:7/10/2014)... new alliance will see the two universities and NPL ... with business and industry and their complementary academic strengths., ... help to shape the scientific priorities of the UK. ... up to 300 high-calibre PhD students, will provide a ... NPL, the potential of the Laboratory will be grown ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... AMRND ) today announced that, at a General ... reverse split of each of its Ordinary,Shares. The reverse ... January 17, 2008., Thomas Lynch, Amarin Chairman and ... that over 95% of the votes cast by our,shareholders ...
... Jan. 18 International Group, Ltd.,(Bloomberg: BIG SP, ... received Conformite Europeenne (CE) Mark approval for its,BioMatrix(R) ... the European Union and the countries in Asia ... BioMatrix drug-eluting stent system,developed internally by the Company, ...
... Kensey Nash Corporation,(Nasdaq: KNSY ) is scheduled ... Emerging Growth Institutional Investor Forum at the Ritz-Carlton ... Wendy F. DiCicco, Kensey Nash,s CFO, will ... (ET). The presentation,materials will be available on the ...
Cached Biology Technology:Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 2Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 3Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 4Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 5Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 6Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 7Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 8Amarin Provides Business Update and Announces Implementation of Reverse Stock Split 9Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 2Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 3Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 4
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... streams could spell the end of spring-run Chinook salmon ... to a study by scientists at UC Davis, the ... Research. There are options for managing water resources ... hydroelectric power generation, said Lisa Thompson, director of the ...
... PHILADELPHIA (September 1, 2011) Our immune system is ... for years, even decades, after they have first been encountered ... a month, we retain the means of making them for ... poorly understood, but researchers at The Wistar Institute have discovered ...
... , Key international experts in the bone field are ... upcoming European Congress on Osteoporosis & Osteoarthritis (IOF-ECCEO12). As ... will present the latest research and clinical advances in ... a joint event of the International Osteoporosis Foundation (IOF) ...
Cached Biology News:Warming streams could be the end for salmon 2Persistent immunity: Wistar researchers find signals that preserve anti-viral antibodies 2Persistent immunity: Wistar researchers find signals that preserve anti-viral antibodies 3European Congress on Osteoporosis & Osteoarthritis opens online registration 2
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
... Solutions has now entered the next frontier ... partnering up with Cellomics, Inc. The drug ... of Beckman Coulter‘s automated solutions systems and ... information at the sub-cellular level. The integration ...
... research and biologic production demands on cell ... confirming viable cell populations. Therefore, both cell ... be determined accurately and precisely. The new ... and cost effective means to perform the ...
... powerful yet simple technology for labeling peptides, ... provides the heterobifunctional linkers SFB and SANH ... It enables conjugation of various tags including ... a variety of proteins. , ...
Biology Products: